JP2021519321A5 - - Google Patents

Info

Publication number
JP2021519321A5
JP2021519321A5 JP2020552234A JP2020552234A JP2021519321A5 JP 2021519321 A5 JP2021519321 A5 JP 2021519321A5 JP 2020552234 A JP2020552234 A JP 2020552234A JP 2020552234 A JP2020552234 A JP 2020552234A JP 2021519321 A5 JP2021519321 A5 JP 2021519321A5
Authority
JP
Japan
Prior art keywords
formulation
pharmaceutical composition
approximately
peptide
aqueous pharmaceutical
Prior art date
Application number
JP2020552234A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021519321A (ja
JPWO2019191264A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/024331 external-priority patent/WO2019191264A1/en
Publication of JP2021519321A publication Critical patent/JP2021519321A/ja
Publication of JP2021519321A5 publication Critical patent/JP2021519321A5/ja
Publication of JPWO2019191264A5 publication Critical patent/JPWO2019191264A5/ja
Abandoned legal-status Critical Current

Links

JP2020552234A 2018-03-27 2019-03-27 ペプチド含有製剤 Abandoned JP2021519321A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862648746P 2018-03-27 2018-03-27
US62/648,746 2018-03-27
PCT/US2019/024331 WO2019191264A1 (en) 2018-03-27 2019-03-27 Peptide-containing formulations

Publications (3)

Publication Number Publication Date
JP2021519321A JP2021519321A (ja) 2021-08-10
JP2021519321A5 true JP2021519321A5 (https=) 2022-03-31
JPWO2019191264A5 JPWO2019191264A5 (https=) 2022-03-31

Family

ID=66103053

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020552234A Abandoned JP2021519321A (ja) 2018-03-27 2019-03-27 ペプチド含有製剤

Country Status (11)

Country Link
US (1) US11517608B2 (https=)
EP (1) EP3773627A1 (https=)
JP (1) JP2021519321A (https=)
KR (1) KR20200139723A (https=)
CN (1) CN112040958A (https=)
AU (1) AU2019243724A1 (https=)
CA (1) CA3097341A1 (https=)
IL (1) IL277466A (https=)
MX (1) MX2020010085A (https=)
TW (1) TW202002996A (https=)
WO (1) WO2019191264A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113876929B (zh) * 2021-11-22 2024-02-23 中国人民解放军陆军军医大学 肽MOTS-c在制备治疗帕金森药物中的应用
CN115444926A (zh) * 2022-05-10 2022-12-09 江南大学 MOTS-c肽及其衍生物在制备放射性肺损伤治疗药物中的应用
CN118236470A (zh) * 2024-03-29 2024-06-25 无锡市第二人民医院 MOTS-c肽及其衍生物在制备支气管哮喘治疗药物中的应用
CN119241659B (zh) * 2024-10-08 2025-09-19 西北大学 MOTS-c及其氨基酸突变多肽在伤口愈合方面的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001076532A2 (en) 2000-04-11 2001-10-18 Cogent Neuroscience, Inc. Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
US8309525B2 (en) 2007-05-30 2012-11-13 Albert Einstein College Of Medicine Of Yeshiva University Treatment of type 2 diabetes, metabolic syndrome, myocardial injury and neurodegeneration with humanin and analogs thereof
AU2008269954A1 (en) 2007-06-29 2009-01-08 Centocor Ortho Biotech Inc. Anti- MCP-1 antibodies, compositions, methods and uses
US7998928B2 (en) 2007-09-14 2011-08-16 The Regents Of The University Of California Method of treatment of type-1 diabetes with a humanin analogue
WO2009135165A2 (en) 2008-05-01 2009-11-05 The Regents Of The University Of California Small humanin-like peptides
WO2012009709A1 (en) 2010-07-16 2012-01-19 Sudhir Paul Hiv cd4 binding site based covalent immunogen compositions
US20130123168A1 (en) 2011-06-17 2013-05-16 The Regents Of The University Of California Humanin and humanin-analogues for the management of atherosclerosis
BR112015023500B1 (pt) * 2013-03-15 2021-01-12 The Regents Of The University Of California composição farmacêutica
TW201819398A (zh) * 2016-09-28 2018-06-01 美商寇峇有限公司 治療性肽

Similar Documents

Publication Publication Date Title
JP2021519321A5 (https=)
CN102274492B (zh) 骨合成代谢蛋白质的药物递送方法
CN102718858B (zh) 胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用
JPH02101022A (ja) 糖尿病治療用医薬組成物
AU2560695A (en) A pharmaceutical preparation comprising glucagon
RU2013139651A (ru) Новые соединения, влияющие на пищевое поведение
JP2002544241A (ja) 生体活性剤の改良された細胞取り込み
TW201127395A (en) Pharmaceutical composition comprising a GLP-1 agonist and methionine
TW201105346A (en) Heat-stable and vibration-stable insulin preparations
CN102727861A (zh) T-细胞介导的疾病的治疗
ES2324009B1 (es) Composicion farmaceutica de liberacion sostenida de somatostatina o un analogo suyo.
US20140371141A1 (en) Insulin glargine/lixisenatide fixed ratio formulation
JP2014515747A (ja) 医薬組成物
ES2952519T3 (es) Polipéptidos cíclicos, su procedimiento de obtención y su aplicación en terapéutica
JPWO2019191264A5 (https=)
CN102133200B (zh) 一种人类松弛素-2 Relaxin的注射用冻干粉制剂
TW201733608A (zh) 含有環狀二肽之神經性疾病之預防用組成物
AU2009218060B2 (en) Pharmaceutical composition for transnasal administration
CN101671390A (zh) 人干扰素α衍生物及其聚乙二醇化修饰物的制备和用途
JP2009528303A5 (https=)
CN108339116B (zh) 壬二酸的应用、含有壬二酸的佐剂和疫苗剂
Wen Advances and challenges in the dosage form design for the treatment of Parkinson's disease
JPH05170664A (ja) 安定なペプチド医薬組成物
CN108025042A (zh) PTHrP类似物的新型制剂
JP2681121B2 (ja) L−グルタミンのオリゴペプチド配合栄養組成物